Christian Strupp
Research Subjects
Christian Strupp has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
Klaus Weber
AnaPath Services GmbH/K. Weber Consulting GmbH, Oberbuchsiten, Switzerland
4 shared publicationsSamuel M. Cohen
Department of Pathology, Microbiology and Immunology, and the Buffett Cancer Center, Sylvia Havlik Centennial Professor of Oncology, University of Nebraska Medical Center, Omaha, NE, 68198-3135, USA
4 shared publicationsC. Wiemann
BASF Oesterreich GmbH, Austria
3 shared publications- Lysiane Richert
KaLy-Cell, 67115, Plobsheim, France
3 shared publications P. Fisher
Bayer CropScience, France
3 shared publicationsR. Parr-Dobrzanski
Syngenta Ltd., UK
3 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Elsevier in Environment International
- Vol. 217
Reduced regulatory testing of biochemical plant protection products: an evaluation using three case studies
- 8 October 2026
- Published by Elsevier in Environment International
- Vol. 217
Open AccessReduced regulatory testing of biochemical plant protection products: an evaluation using three case studies
- Open Access
- 5 May 2026
- Published by Springer Nature in Archives of Toxicology
- Vol. 100 (8) , 3759-3775
The use of cultured human hepatocytes as a test system to evaluate cell proliferation as a key event in nongenotoxic carcinogenesis
The objective of this study was to evaluate the applicability of replicative DNA synthesis (RDS) in cultured human hepatocytes as an in vitro model to evaluate the carcinogenicity of nongenotoxic chemicals and species differences. Investigations were performed with 39 cryopreserved human hepatocyte preparations from predominantly Caucasian male and female donors aged 10 months to 80 years and were conducted by two separate laboratories, which employed different culture conditions and methodology for evaluating effects on hepatocyte RDS. For all male and female human hepatocyte preparations of all ages examined, treatment with either epidermal growth factor (EGF) and/or hepatocyte growth factor (HGF) resulted in a stimulation of RDS. In contrast, the treatment of human hepatocytes with the constitutive androstane receptor (CAR) activators phenobarbital and CITCO and the peroxisome proliferator-activated receptor alpha (PPARα) activator WY-14,643 did not result in any increases in RDS. These findings are in agreement with previous studies where, unlike EGF and HGF, nongenotoxic CAR and PPARα activators are mitogenic agents in rodent but not in human hepatocytes. While some donor to donor variability was observed, the qualitative inducibility of RDS by EGF and/or HGF in human hepatocytes was not sex-, age-, or, based on a limited number of samples examined, ethnicity-dependent. These studies demonstrate that cultured cryopreserved human hepatocytes are an established, reproducible and relevant in vitro test system for investigating the nongenotoxic carcinogenic potential of chemicals and species differences, and worth progressing to formal validation according to OECD principles.
- 5 May 2026
- Published by Springer Nature in Archives of Toxicology
- Vol. 100 (8) , 3759-3775
Open AccessThe use of cultured human hepatocytes as a test system to evaluate cell proliferation as a key event in nongenotoxic carcinogenesis
The objective of this study was to evaluate the applicability of replicative DNA synthesis (RDS) in cultured human hepatocytes as an in vitro model to evaluate the carcinogenicity of nongenotoxic chemicals and species differences. Investigations were performed with 39 cryopreserved human hepatocyte preparations from predominantly Caucasian male and female donors aged 10 months to 80 years and were conducted by two separate laboratories, which employed different culture conditions and methodology for evaluating effects on hepatocyte RDS. For all male and female human hepatocyte preparations of all ages examined, treatment with either epidermal growth factor (EGF) and/or hepatocyte growth factor (HGF) resulted in a stimulation of RDS. In contrast, the treatment of human hepatocytes with the constitutive androstane receptor (CAR) activators phenobarbital and CITCO and the peroxisome proliferator-activated receptor alpha (PPARα) activator WY-14,643 did not result in any increases in RDS. These findings are in agreement with previous studies where, unlike EGF and HGF, nongenotoxic CAR and PPARα activators are mitogenic agents in rodent but not in human hepatocytes. While some donor to donor variability was observed, the qualitative inducibility of RDS by EGF and/or HGF in human hepatocytes was not sex-, age-, or, based on a limited number of samples examined, ethnicity-dependent. These studies demonstrate that cultured cryopreserved human hepatocytes are an established, reproducible and relevant in vitro test system for investigating the nongenotoxic carcinogenic potential of chemicals and species differences, and worth progressing to formal validation according to OECD principles.
- Open Access
- 15 July 2025
- Published by Elsevier in Environment International
- Vol. 203, 109675
A Scheme for Safety Testing and Assessment of Biochemicals under the EU Plant Protection Products Regulation (BiochemPPP-STAS)
- 15 July 2025
- Published by Elsevier in Environment International
- Vol. 203, 109675
Open AccessA Scheme for Safety Testing and Assessment of Biochemicals under the EU Plant Protection Products Regulation (BiochemPPP-STAS)
- Open Access
- 30 January 2025
- Published by SAGE Publications in Human & Experimental Toxicology
- Vol. 44
Conflicts of interest in the International Agency for Research on Cancer process of identifying carcinogenic hazards to humans
Managing conflicts of interest (COIs) in scientific decision-making is important for minimizing bias and fostering public trust in science. Proper management of COIs has added significance when scientists are making decisions that impact public policy, such as assessing substances for carcinogenicity. The International Agency for Research on Cancer (IARC) organizes expert working groups to identify putative carcinogens and determine whether or not the hazard is likely to present significant potential harm to humans. While IARC has policies for managing COIs, prior professional experience with the substance being assessed is not defined as a COI. Indeed, IARC working group members are chosen based on subject matter expertise, including prior publication on the substance under review. However, a person’s prior experience with a substance poses a significant potential COI by equipping them with strong pre-existing views about the substance’s toxicity and carcinogenicity. To minimize the risk of bias in IARC working groups, participants with voting powers should be independent scientific experts with sufficient professional experience to review carcinogenicity data but with no substantial prior experience with the substance under review. A related IARC practice restricting data review by working groups to selected publications is another significant COI. Instead, all accessible data should be available for consideration by working groups in assessing the carcinogenic hazard of substances. Another recommendation to reduce potential bias would be to reinstate the option of “probably not carcinogenic to humans”.
- 30 January 2025
- Published by SAGE Publications in Human & Experimental Toxicology
- Vol. 44
Open AccessConflicts of interest in the International Agency for Research on Cancer process of identifying carcinogenic hazards to humans
Managing conflicts of interest (COIs) in scientific decision-making is important for minimizing bias and fostering public trust in science. Proper management of COIs has added significance when scientists are making decisions that impact public policy, such as assessing substances for carcinogenicity. The International Agency for Research on Cancer (IARC) organizes expert working groups to identify putative carcinogens and determine whether or not the hazard is likely to present significant potential harm to humans. While IARC has policies for managing COIs, prior professional experience with the substance being assessed is not defined as a COI. Indeed, IARC working group members are chosen based on subject matter expertise, including prior publication on the substance under review. However, a person’s prior experience with a substance poses a significant potential COI by equipping them with strong pre-existing views about the substance’s toxicity and carcinogenicity. To minimize the risk of bias in IARC working groups, participants with voting powers should be independent scientific experts with sufficient professional experience to review carcinogenicity data but with no substantial prior experience with the substance under review. A related IARC practice restricting data review by working groups to selected publications is another significant COI. Instead, all accessible data should be available for consideration by working groups in assessing the carcinogenic hazard of substances. Another recommendation to reduce potential bias would be to reinstate the option of “probably not carcinogenic to humans”.
- Open Access
- 26 August 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (17) , 13246
Increased Cell Proliferation as a Key Event in Chemical Carcinogenesis: Application in an Integrated Approach for the Testing and Assessment of Non-Genotoxic Carcinogenesis
In contrast to genotoxic carcinogens, there are currently no internationally agreed upon regulatory tools for identifying non-genotoxic carcinogens of human relevance. The rodent cancer bioassay is only used in certain regulatory sectors and is criticized for its limited predictive power for human cancer risk. Cancer is due to genetic errors occurring in single cells. The risk of cancer is higher when there is an increase in the number of errors per replication (genotoxic agents) or in the number of replications (cell proliferation-inducing agents). The default regulatory approach for genotoxic agents whereby no threshold is set is reasonably conservative. However, non-genotoxic carcinogens cannot be regulated in the same way since increased cell proliferation has a clear threshold. An integrated approach for the testing and assessment (IATA) of non-genotoxic carcinogens is under development at the OECD, considering learnings from the regulatory assessment of data-rich substances such as agrochemicals. The aim is to achieve an endorsed IATA that predicts human cancer better than the rodent cancer bioassay, using methodologies that equally or better protect human health and are superior from the view of animal welfare/efficiency. This paper describes the technical opportunities available to assess cell proliferation as the central gateway of an IATA for non-genotoxic carcinogenicity.
- 26 August 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (17) , 13246
Open AccessIncreased Cell Proliferation as a Key Event in Chemical Carcinogenesis: Application in an Integrated Approach for the Testing and Assessment of Non-Genotoxic Carcinogenesis
In contrast to genotoxic carcinogens, there are currently no internationally agreed upon regulatory tools for identifying non-genotoxic carcinogens of human relevance. The rodent cancer bioassay is only used in certain regulatory sectors and is criticized for its limited predictive power for human cancer risk. Cancer is due to genetic errors occurring in single cells. The risk of cancer is higher when there is an increase in the number of errors per replication (genotoxic agents) or in the number of replications (cell proliferation-inducing agents). The default regulatory approach for genotoxic agents whereby no threshold is set is reasonably conservative. However, non-genotoxic carcinogens cannot be regulated in the same way since increased cell proliferation has a clear threshold. An integrated approach for the testing and assessment (IATA) of non-genotoxic carcinogens is under development at the OECD, considering learnings from the regulatory assessment of data-rich substances such as agrochemicals. The aim is to achieve an endorsed IATA that predicts human cancer better than the rodent cancer bioassay, using methodologies that equally or better protect human health and are superior from the view of animal welfare/efficiency. This paper describes the technical opportunities available to assess cell proliferation as the central gateway of an IATA for non-genotoxic carcinogenicity.
- Open Access
- 3 July 2023
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 53 (6) , 339-371
Towards a science-based testing strategy to identify maternal thyroid hormone imbalance and neurodevelopmental effects in the progeny – Part IV: the ECETOC and CLE Proposal for a Thyroid Function-Related Neurodevelopmental Toxicity Testing and Assessment Scheme (Thyroid-NDT-TAS)
Following the European Commission Endocrine Disruptor Criteria, substances shall be considered as having endocrine disrupting properties if they (a) elicit adverse effects, (b) have endocrine activity, and (c) the two are linked by an endocrine mode-of-action (MoA) unless the MoA is not relevant for humans. A comprehensive, structured approach to assess whether substances meet the Endocrine Disruptor Criteria for the thyroid modality (EDC-T) is currently unavailable. Here, the European Centre for Ecotoxicology and Toxicology of Chemicals Thyroxine Task Force and CropLife Europe propose a Thyroid Function-Related Neurodevelopmental Toxicity Testing and Assessment Scheme (Thyroid-NDT-TAS). In Tier 0, before entering the Thyroid-NDT-TAS, all available in vivo, in vitro and in silico data are submitted to weight-of-evidence (WoE) evaluations to determine whether the substance of interest poses a concern for thyroid disruption. If so, Tier 1 of the Thyroid-NDT-TAS includes an initial MoA and human relevance assessment (structured by the key events of possibly relevant adverse outcome pathways) and the generation of supportive in vitro/in silico data, if relevant. Only if Tier 1 is inconclusive, Tier 2 involves higher-tier testing to generate further thyroid- and/or neurodevelopment-related data. Tier 3 includes the final MoA and human relevance assessment and an overarching WoE evaluation to draw a conclusion on whether, or not, the substance meets the EDC-T. The Thyroid-NDT-TAS is based on the state-of-the-science, and it has been developed to minimise animal testing. To make human safety assessments more accurate, it is recommended to apply the Thyroid-NDT-TAS during future regulatory assessments.
- 3 July 2023
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 53 (6) , 339-371
Open AccessTowards a science-based testing strategy to identify maternal thyroid hormone imbalance and neurodevelopmental effects in the progeny – Part IV: the ECETOC and CLE Proposal for a Thyroid Function-Related Neurodevelopmental Toxicity Testing and Assessment Scheme (Thyroid-NDT-TAS)
Following the European Commission Endocrine Disruptor Criteria, substances shall be considered as having endocrine disrupting properties if they (a) elicit adverse effects, (b) have endocrine activity, and (c) the two are linked by an endocrine mode-of-action (MoA) unless the MoA is not relevant for humans. A comprehensive, structured approach to assess whether substances meet the Endocrine Disruptor Criteria for the thyroid modality (EDC-T) is currently unavailable. Here, the European Centre for Ecotoxicology and Toxicology of Chemicals Thyroxine Task Force and CropLife Europe propose a Thyroid Function-Related Neurodevelopmental Toxicity Testing and Assessment Scheme (Thyroid-NDT-TAS). In Tier 0, before entering the Thyroid-NDT-TAS, all available in vivo, in vitro and in silico data are submitted to weight-of-evidence (WoE) evaluations to determine whether the substance of interest poses a concern for thyroid disruption. If so, Tier 1 of the Thyroid-NDT-TAS includes an initial MoA and human relevance assessment (structured by the key events of possibly relevant adverse outcome pathways) and the generation of supportive in vitro/in silico data, if relevant. Only if Tier 1 is inconclusive, Tier 2 involves higher-tier testing to generate further thyroid- and/or neurodevelopment-related data. Tier 3 includes the final MoA and human relevance assessment and an overarching WoE evaluation to draw a conclusion on whether, or not, the substance meets the EDC-T. The Thyroid-NDT-TAS is based on the state-of-the-science, and it has been developed to minimise animal testing. To make human safety assessments more accurate, it is recommended to apply the Thyroid-NDT-TAS during future regulatory assessments.
- 22 February 2023
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 139, 105362
Letter to the Editors regarding “10% body weight (gain) change as criterion for the maximum tolerated dose: A critical analysis”
- 22 February 2023
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 139, 105362
Letter to the Editors regarding “10% body weight (gain) change as criterion for the maximum tolerated dose: A critical analysis”
- Open Access
- 17 February 2023
- Published by Springer Nature in Archives of Toxicology
- Vol. 97 (4) , 991-999
Species differences and human relevance of the toxicity of 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitors and a new approach method in vitro for investigation
The mode of action (MoA) of the 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor herbicides in mammals is well described and is generally accepted to be due to a build-up of excess systemic tyrosine which is associated with the range of adverse effects reported in laboratory animals. What is less well accepted is the basis for the marked difference in the effects of HPPD inhibitors that has been observed across experimental species and humans, where some species show significant toxicities whereas in other species exposure causes few effects. The activity of the catabolic enzyme tyrosine aminotransferase (TAT) varies across species including humans and it is hypothesized that this primarily accounts for the different levels of tyrosinemia observed between species and leads to the subsequent differences in toxicity. The previously reported activities of TAT in different species showed large variation, were inconsistent, have methodological uncertainties and could lead to a reasonable challenge to the scientific basis for the species difference in response. To provide clarity, a new method was developed for the simultaneous and systematic measurement of TAT in vitro using robust methodologies in a range of mammalian species including human. The results obtained showed general correlation between high TAT activity and low in vivo toxicity when using a model based on hepatic cytosol and a very convincing correlation when using a primary hepatocyte model. These data fully support the role of TAT in explaining the species differences in toxicity. Moreover, this information should give greater confidence in selecting the most appropriate animal model (the mouse) for human health risk assessment and for key classification and labeling decision-making.
- 17 February 2023
- Published by Springer Nature in Archives of Toxicology
- Vol. 97 (4) , 991-999
Open AccessSpecies differences and human relevance of the toxicity of 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitors and a new approach method in vitro for investigation
The mode of action (MoA) of the 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor herbicides in mammals is well described and is generally accepted to be due to a build-up of excess systemic tyrosine which is associated with the range of adverse effects reported in laboratory animals. What is less well accepted is the basis for the marked difference in the effects of HPPD inhibitors that has been observed across experimental species and humans, where some species show significant toxicities whereas in other species exposure causes few effects. The activity of the catabolic enzyme tyrosine aminotransferase (TAT) varies across species including humans and it is hypothesized that this primarily accounts for the different levels of tyrosinemia observed between species and leads to the subsequent differences in toxicity. The previously reported activities of TAT in different species showed large variation, were inconsistent, have methodological uncertainties and could lead to a reasonable challenge to the scientific basis for the species difference in response. To provide clarity, a new method was developed for the simultaneous and systematic measurement of TAT in vitro using robust methodologies in a range of mammalian species including human. The results obtained showed general correlation between high TAT activity and low in vivo toxicity when using a model based on hepatic cytosol and a very convincing correlation when using a primary hepatocyte model. These data fully support the role of TAT in explaining the species differences in toxicity. Moreover, this information should give greater confidence in selecting the most appropriate animal model (the mouse) for human health risk assessment and for key classification and labeling decision-making.
- 1 November 2020
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 117, 104758
Weight of evidence and human relevance evaluation of the benfluralin mode of action in rodents (Part I): Liver carcinogenesis
- 1 November 2020
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 117, 104758
Weight of evidence and human relevance evaluation of the benfluralin mode of action in rodents (Part I): Liver carcinogenesis
- 1 November 2020
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 117, 104736
Weight of Evidence and Human Relevance Evaluation of the Benfluralin Mode of Action in Rats (Part II): Thyroid carcinogenesis
- 1 November 2020
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 117, 104736
Weight of Evidence and Human Relevance Evaluation of the Benfluralin Mode of Action in Rats (Part II): Thyroid carcinogenesis